Chemistry:Umeclidinium bromide

From HandWiki
Short description: Chemical compound
Umeclidinium bromide
Umeclidinium bromide.svg
Umeclidinium bromide 3D.png
Clinical data
Trade namesIncruse Ellipta
Other namesGSK573719A
License data
Routes of
administration
Inhalation (DPI)
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only) [1]
  • UK: POM (Prescription only)
  • US: ℞-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding~89%[2]
MetabolismLiver (CYP2D6)
Elimination half-life11 hours
ExcretionFeces (58%) and urine (22%)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
Chemical and physical data
FormulaC29H34BrNO2
Molar mass508.500 g·mol−1
3D model (JSmol)

Umeclidinium bromide, sold under the brand name Incruse Ellipta, is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD).[2] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol)[3][4] and also as a triple-therapy combination as fluticasone furoate/umeclidinium bromide/vilanterol.[5]

It is on the World Health Organization's List of Essential Medicines.[6] In 2020, it was the 245th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[7][8]

References

External links